Direct analysis reveals an absence of γ-carboxyglutamic acid in cancer procoagulant from human tissues

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 315-320

  Kaplinska, Katarzyna ^a   Mielicki, Wojciech P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

carboxyglutamic acid; Cancer procoagulant; Thrombosis; Warfarin

Indexed keywords

4 CARBOXYGLUTAMIC ACID; BLOOD CLOTTING FACTOR 10; CANCER PROCOAGULANT; MONOCLONAL ANTIBODY;

AMNION; ARTICLE; BLOOD CLOTTING; CHORION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME ISOLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL;

1-CARBOXYGLUTAMIC ACID; AMNION; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CELL LINE, TUMOR; CHORION; CYSTEINE ENDOPEPTIDASES; ENZYME ACTIVATION; FACTOR X; FEMALE; HUMANS; MELANOMA; NEOPLASM PROTEINS; PREGNANCY; WARFARIN;

EID: 68149147588     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32831bc2c5     Document Type: Article

References (39)

1. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res 2007; 120 (Suppl):S99-S106.
2. Zamagni E, Valdre L, Palareti G, Cavo M. Prevention of VTE in multiple myeloma patients. Thromb Res2007; 120 (Suppl):S133-S136.
3. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16:696-701.
4. Donati MB. Pathogenesis of thrombosis in cancer. Vessels 1996; 4:4-8.
5. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25:1545-1550.
6. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981; 67:1665-1671.
7. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patients. Semin Thromb Hemost 1999; 25:173-182.
8. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res2001; 102:V215-V224.
9. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who receive adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286-294.
10. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecularweight heparin therapy in cancer patients. Oncologist 2005; 10:72-79.
11. Falls LA, Furie BC, Jacobs M, Furie B, Rigby AC. The ω-loop region of the human prothrombin γ-carboxyglutamic acid domain penetrates anionic phospholipid membranes. J Biol Chem 2001; 276:23895-23902.
12. Hackeng TM. Gla glances at proteins. Blood 2005; 105:1-2.
13. Colucci M, Delaini F, de Bellis Vitti G, Locati D, Poggi A, Semeraro N, et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983; 32:1689-1691.
14. Hejna M, Radere M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91:22-36.
15. Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8:73-86.
16. Mielicki WP, Kozwich DL, Kramer LC, Gordon SG. Effectofdivalent ions on the activity of cancer procoagulant. Arch Biochem Biophys 1994; 314:165-170.
17. Mielicki WP, Gordon SG. Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coagul Fibrinolysis 1993; 4: 441-446.
18. Roncaglioni MC, Dalessandro AP, Casali B, Vermeer C, Donati MB. Gamma-glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. Haemostasis 1986; 16:295-299.
19. Roncaglioni MC, Falanga A, D'lessandro AP, Alessio MG, Casali B, Donati MB. Evidence of warfarin-sensitive cancer procoagulant in V2 carcinoma. Haematologica 1989; 74:143-147.
20. Gordon SG, Hasiba A, Cross BA, Poole MA, Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66:1261-1265.
21. Mielicki WP, Mielicka E, Gordon SG. Cancer procoagulant activity studies using synthetic chromogenic substrates. Thromb Res1997; 87:251-256.
22. Mielicki WP, Sobolewska M. Cancer procoagulant (EC 3.4.22.26): the kinetics of its inhibition by E-64 and modulation of the activity by cadmium, cooper and tin ions. Cancer Res Ther Ctrl 2001; 11:135-141.
23. Towbin H, Staechelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4354.
24. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Gambacorti Passerini C, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92:143-151.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophag T4. Nature 1970; 227:680-685.
26. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82:165-174.
27. Mann KG. Thrombin formation. Chest 2003; 124 (Suppl):4S-10S.
28. Zwicker JL, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126-136.
29. Stief TW. Kallikrein activates prothrombin. Clin Appl Thromb Haemost 2008; 14:97-98.
30. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98:120-125.
31. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 1999; 93:1798-1808.
32. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2:2118-2132.
33. Vermeer C, De Boer-Van den Berg MA. Vitamin K-dependent carboxylase. Haematologia (Budap) 1985; 18:71-97.
34. Hauschka PV, Haroon Y, Buchthal SD, Bell RG. Vitamin K-dependent processes in tumor cells. Haemostasis 1986; 16:273-278.
35. Pecci L, De Marco V, Cavallini D. Gamma-carboxyglutamic acid content in human kidney and placenta. Biochem Int 1983; 6:593-598.
36. Lorenzet R, Bottazzi B, Locati D, Colucci M, Mantovani A, Semeraro N. Failure to warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. Eur J Cancer Clin Oncol 1985; 21:263-265.
37. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53:505-518.
38. Falanga A, Gordon SG. Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant. Biochim Biophys Acta 1985; 831:161-165.
39. Kaplinska K, Kamocka M, Rosen ED, Mielicki WP. Comparison of the enzymatic and immunological properties of direct factor X-activator isolated from human and swine amnion-chorion membranes and from rat prostate cancer. Acta Haematol Pol 2007; 38:331-338.